Scholarlink

<p>Dendritic cells (DCs) play a pivotal role in regulating immune responses, influencing both pro-inflammatory and anti-inflammatory environments. Given the critical role of the COX-2/PEG2 pathway in regulating DC maturation and cytokine production, we investigated whether selective COX-2 inhibition by celecoxib could shift human monocyte-derived dendritic cells (mDCs) toward a toerogenic profile. The impact of celecoxib treatment on the expression of various inflammatory and anti-inflammatory factors, including IL-12, TNF-α, IL-10, IDO, TGF-β, and STAT3, was evaluated. Our results demonstrate that the expression of key anti-inflammatory factors was enhanced in DCs, suggesting that COX-2 inhibition could promote a tolerogenic phenotype. In conclusion, the therapeutic modulation of DCs through COX-2 inhibition could have applications beyond autoimmune diseases, offering potential for broader immunomodulatory therapies. Further studies are required to validate these findings and explore clinical applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Celecoxib modulates inflammatory and immunoregulatory gene expression in human monocyte-derived dendritic cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Vida Hashemi,
  • Behzad Baradaran,
  • Bahar Naseri,
  • Javad Masoumi,
  • Elham Baghbani,
  • Nazila Alizadeh,
  • Mahya Zolfaghar Ghoshooni,
  • Arezoo Hosseini

摘要

Dendritic cells (DCs) play a pivotal role in regulating immune responses, influencing both pro-inflammatory and anti-inflammatory environments. Given the critical role of the COX-2/PEG2 pathway in regulating DC maturation and cytokine production, we investigated whether selective COX-2 inhibition by celecoxib could shift human monocyte-derived dendritic cells (mDCs) toward a toerogenic profile. The impact of celecoxib treatment on the expression of various inflammatory and anti-inflammatory factors, including IL-12, TNF-α, IL-10, IDO, TGF-β, and STAT3, was evaluated. Our results demonstrate that the expression of key anti-inflammatory factors was enhanced in DCs, suggesting that COX-2 inhibition could promote a tolerogenic phenotype. In conclusion, the therapeutic modulation of DCs through COX-2 inhibition could have applications beyond autoimmune diseases, offering potential for broader immunomodulatory therapies. Further studies are required to validate these findings and explore clinical applications.